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This paper was commissioned by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) to provide background information to inform and 
contribute to the drafting of Health and social responses to drug problems: a 
European guide.  
 
This background paper was produced under contract CT.16.SDI.0139.1.0 and we are 
grateful for the valuable contribution of the author. The paper has been cited within 
Health and social responses to drug problems and is also being made available online 
for those who would like further information on the topic. However, the views, 
interpretations and conclusions set out in this publication are those of the author 
and are not necessarily those of the EMCDDA or its partners, any EU Member State 
or any agency or institution of the European Union.  
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1. Introduction 
 
The aim of this paper is to focus on the harmful interaction between 
psychoactive drug use and sexual activity. It is acknowledged that in some 
individuals co-occurrence of drug consumption and sexual activity causes no 
apparent harm, but this group will not be considered here.  
 
To understand the harmful interaction between drug consumption and sexual 
activity, and to consider its implications for treatment needs, this briefing paper 
will address the following questions: 
 
• How do sexual activity and psychoactive drug use interact to cause harm? 
 
• Are problems relating to co-occurring drug use and sexual activity a cause 
for concern?  
 
• How are services currently configured across Europe for those with 
problems relating to co-occurring drug use and sexual activity?  
 
• What could an improved service look like? 
 
• Are there examples of innovative responses to co-occurring problematic 
drug use and sexual activity from across Europe? 
 
• What steps need to be taken to improve the care of people with problems 
relating to co-occurring drug use and sexual activity? 
 
This briefing paper will focus largely on treatment interventions and will not 
specifically address issues such as general population screening and prevention. 
There is not scope to consider the role of alcohol, although there is a sizeable 
literature examining the interaction between alcohol and sexual activity. Alcohol 
and drugs are often consumed together, however, and the risks typically increase 
when more than one psychoactive substance is used simultaneously. 
 
Two concepts of harm will be used throughout.  
 
Harm related to drug use 
Psychoactive drugs can be consumed without apparent harm, and this is often 
termed ‘recreational’ drug use. When drug use causes harm, whether physical, 
psychological or social, it is often termed ‘drug misuse’. The severity of harm is 
categorised using World Health Organization (WHO) criteria and defined as 
‘harmful’ or ‘dependent’ (WHO, 1992). 
 
Harm related to sexual activity 
Sexual activity typically results in no apparent harm. There are, however, 
examples of harm that are directly or indirectly related to sexual activity. 
Examples include the acquiring and onward transmission of infection diseases 
such as gonorrhoea, and sexual activity that results in physical trauma or 
psychological distress. 
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2. How do sexual activities and psychoactive drug use interact to cause 
harm? 
 
The interaction between sexual activity and drug use can be complex, but in 
most people results in no apparent harm. In some people, however, the 
interaction leads to drug- or sexual-related harms, or both. Broadly speaking, 
there are four models that describe these harmful interactions. 
 
Model 1 
Drug use leads to intoxication and disinhibition. While in a state of intoxication, 
the individual engages in unintended sexual activities that may or may not be 
consensual but which are regretted once the intoxicating effect has worn off. 
Crucially, the sexual activity was not the intention when the drug was consumed, 
but took place as a result of drug intoxication. Sexual activity (or a specific aspect 
of it, such as no condom use) would be unlikely to have occurred unless the drug 
was consumed.  
 
Example: cocaine intoxication leading to sexual assault. 
 
Particular risks: pregnancy, sexually transmitted infections (STIs), sexual 
assault. 
 
Model 2 
People with established harmful or dependent drug misuse problems engage in 
activities that either directly or indirectly put their sexual health at risk. 
 
Example: To fund drug use, people are drawn into the sex industry, leading to an 
increased risk of STIs and sexual assault. 
 
Particular risks: STIs including those caused by blood-borne viruses (BBVs), 
drug overdose, sexual assault. 
 
Model 3 
Psychoactive drugs are used immediately before or during sex with the specific 
intention of enhancing sexual performance and pleasure. Sexual activity is 
directly and deliberately facilitated by drug use. 
 
Example: The consumption of methamphetamine, gamma-hydroxybutyrate 
(GHB)/gamma-butyrolactone (GBL) and mephedrone in the context of sex 
parties (‘chemsex’). 
 
Particular risks: High-risk sexual activity, STIs, sexual assault, harmful or 
dependent drug use, drug overdose. 
 
Model 4 
Drugs are used to cope with the emotional distress associated with a sexual-
related health problem such as a new diagnosis, ongoing debilitating symptoms 
or associated stigma. 
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Example: Newly diagnosed human immunodeficiency virus (HIV) infection, 
leading to harmful substance use to cope with this diagnosis. 
 
Particular risks: Harmful or dependent drug use, mental health problems such 
as depression or post-traumatic stress disorder. 
 
3. Is the co-occurrence of drug use and sexual activity causing significant 
problems in Europe? 
 
As the above examples suggest, the interaction between drug use and sexual 
activity can be complex and cause harm, but how common is this harm?  
 
Psychoactive drug use 
 
Drug use is common, with one in four Europeans estimated to have used an illicit 
drug in their lifetime (EMCDDA, 2016a). Harmful practices vary considerably 
between countries; for example, the prevalence of injecting use ranges from less 
than one up to nine per 1 000 population aged 15 to 64 across Europe. Heroin is 
still the most commonly injected substance, although the prevalence of heroin 
injection has been steadily falling over the last decade in most of Europe. There 
is, however, increasing concern about the injection of amphetamine and novel 
psychoactive substances. 
 
HIV infections attributed to drug injecting have also been falling and are now 
estimated to represent around 4 % of all HIV infections. This figure does not 
include HIV infection attributable to the co-occurrence of non-injecting use and 
high-risk sexual activities, the incidence of which is unknown. The prevalence of 
HIV positivity among injecting drug users is estimated to be around 5 % in 
Europe as a whole, with significant variation between countries. 
 
Rates of hepatitis C virus (HCV) infection among European injecting drug users 
vary between 15 % and 84 %, and in most countries are above 50 %. Worryingly, 
it is thought that many of those affected are unaware that they are infected; 
estimates of the proportion of HCV-positive individuals who fall into this 
category vary from 24 % to 76 %.  
 
Increased risk of problematic drug use is associated with mental health 
problems, men who have sex with men (MSM), young people, socioeconomic 
deprivation, chronic pain and a genetic vulnerability to substance misuse. 
 
Sexual activity 
 
The epidemiology of harms related to sexual activity across Europe is difficult to 
interpret due to heterogeneity of reporting and differences between healthcare 
systems.  
 
Based on available data, rates of STIs vary widely across Europe and, like drug 
use, are highest among young people and MSM (ECDDA, 2016b).  
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Morbidity associated with STIs is related not only to acute infection but also to 
longer-term harms such as pelvic inflammatory disease and infertility. The most 
commonly notified STI in Europe’ is chlamydia, with a prevalence of 182 cases 
per 100 000 population, although the true prevalence may be higher because 
many affected individuals are asymptomatic. 
 
What is the overlap between harms related to drug use and sexual activity? 
 
Current data-reporting structures across Europe make it difficult to link harms 
related to sexual activity and those attributable to drug use, as services provided 
to address these two problems rarely share data collection methods. This makes 
it hard to accurately identify and characterise people with co-occurring 
problems attending both services. There is a need to better understand the size 
of this population, and its profile and treatment needs.  
 
In the United Kingdom, the genitourinary medicine clinical activity dataset 
(GUMCAD) gathers information on attendees at sexual health clinics, who are 
routinely asked ‘Were you under the influence of recreational drugs (before or 
during sex) with any partner in the last 3 months?’. Data from nearly 9 000 
respondents suggest that the prevalence of drug-influenced sexual activity is 
6.6 %. The rate is lower among heterosexual women (4.1 %) and higher among 
MSM (12.1 %) (Mohammed et al., 2016). 
 
Drug services do not routinely collect information on sexual activity. Small 
studies suggest that rates of sexualised drug use may be as high as 73 %, but this 
figure varies widely depending on the treatment population (Bowden-Jones et 
al., 2017). 
 
However, studies that have examined both treatment populations do not 
describe any causation between sexual activity, drug use and harm. There are 
relatively few data to inform the prevalence of harm in people outside treatment 
settings (Bourne et al., 2015; Schmidt et al., 2016). 
 
Despite the challenges of limited data, there is an apparent overlap between the 
two treatment services populations. Young people, MSM and people working 
within the sex industry appear to be at the highest risk of co-occurring harms 
relating to drug use and sexual activity. 
 
4. How are services currently configured across Europe for those with co-
occurring harms relating to drug use and sexual activity? 
 
Across Europe, treatment services for drug and sexual health problems are 
typically funded separately, and services often have different eligibility criteria 
and catchment areas. For example, many sexual health services can be accessed 
anonymously without an appointment, irrespective of home address. Many drug 
treatment services also offer a ‘no appointment’ approach, but in some countries 
access is determined by area of residence. This can result in people who travel to 
a preferred sexual health service being eligible for treatment of their sexual 
health problems but ineligible for care at the nearest drug treatment service, as 
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they are outside the relevant catchment area. Sexual health and drug treatment 
services in Europe are rarely co-located. This may be particularly challenging for 
groups with complex needs for whom ‘joined-up’ care would be particularly 
indicated (e.g. people working in the sex trade, homeless populations and those 
receiving treatment for HIV infection). 
 
There are, however, some advantages to offering specialist sexual health and 
drug treatment services separately. Patients can clearly identify the service they 
wish to attend and will usually have a good idea of what to expect. They are 
unlikely to be surprised by questions about other areas of their lives, which they 
may experience as intrusive. Separate services also allow expertise and funding 
to be focused where they are needed. 
 
The drawbacks of separate services include: 
 
• Staff lack the expertise to correctly identify and assess co-occurring 
problems, which can result in a missed opportunity to intervene. For 
example, a patient attending drug treatment services to receive support 
for cocaine misuse may not be asked about patterns of sexual activity or 
STIs when, in fact, the use of cocaine to facilitate paid sexual activity has 
led to repeated STIs. An opportunity has been missed not only to treat the 
infections but also to fully understand the motivations behind the drug 
use and possible solutions. 
 
• People attending one service may feel unable to disclose the full 
complexity of their issues due to concerns about stigma or lack of 
knowledge among staff. 
 
• A lack of coordination of care between sexual health and drug treatment 
services can cause difficulties for the patient in navigating complex care 
pathways. Some patients, particularly those with severe drug misuse 
problems, will be particularly vulnerable, live chaotic lifestyles and be 
poorly motivated to access care. The lack of centralised care may 
necessitate travelling to different venues for help with different parts of 
the same complex problem. The barriers of travelling time, perceived 
stigma and inconvenience, and the challenge of finding the right help, may 
result in patients with complex needs failing to receive appropriate 
treatment.  
 
• Some attendees of sexual health services believe that drug treatment 
services are ‘just for heroin users’ and that they lack sufficient expertise 
regarding the drugs more commonly used by attendees at sexual health 
services. Indeed, it may well be the case that mainstream drug services 
have limited experience of some types of drugs and patterns of use, for 
example the drugs used in ‘chemsex’, such as GHB/GBL. As a result, some 
groups of drug users, for example MSM who engage in ‘chemsex’, are 
frequently uncertain if drug treatment services can help them. 
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• There is a lack of sharing of expertise between sexual health and drug 
treatment services. Both staff groups receive structured training in their 
specialist area but gain little expertise in managing the complexity of a 
patient with co-occurring problems related to drug misuse and sexual 
activity.  
 
5. What could an improved service look like? 
 
Improving the treatment offered to those with co-occurring harms related to 
drug use and sexual activity can be discussed by considering:  
 
• how such patients are identified; 
 
• what level of assessment is appropriate; 
 
• which interventions should be provided. 
 
The starting point for this discussion is a clear understanding of what each 
service currently offers and whether or not this needs to be enhanced. Table 1. 
shows the interventions offered at present by most services across Europe.  
 
Table 1: Interventions typically offered by sexual health and drug 
treatment services in Europe 
 
Sexual health services Drug treatment services 
Advice on safe sexual practices 
Provision of condoms 
Contraception advice and provision 
Assessment and management of a 
range of harms related to sexual 
activity, including screening and 
treatment of STIs 
Motivational enhancement approaches 
Signposting to other services 
Advice on safer drug use practices 
Needle exchange  
Provision of condoms 
Assessment and management of a 
range of harms related to drug use, 
including opioid substitution 
treatment, medically assisted 
detoxification and relapse prevention 
Motivational enhancement approaches 
Signposting to other services 
 
Interestingly, for both services, a key approach to reducing harm is helping the 
patient modify higher risk behaviours. Although each service focuses on different 
behaviours, this shared expertise in behavioural change is a clear opportunity for 
services to work together using a common therapeutic approach.  
 
What should services be offering to patients with co-occurring harms 
related to drug use and sexual activity? 
 
What could each service routinely add that would improve the care of people 
with harms related to co-occurring drug use and sexual activity? The first step is 
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the detection of a co-existing problem. The provision of advice on avoiding or 
reducing harm should be considered for all people attending services. This could 
be as simple as displaying posters or leaflets with harm reduction advice. At 
assessment, services should be able to enquire about drug use and sexual 
activity, and where this co-occurs further explore possible interactions and their 
impact. 
 
Once a co-occurring problem has been identified, the next step is to define which 
interventions would be appropriate to each setting. It would be unrealistic to 
expect drug treatment services to undertake a detailed sexual health assessment 
and investigations. Likewise, sexual health services cannot be expected to 
complete a detailed assessment of drug harm. Instead, what could be reasonably 
expected of each service?  
 
The following section outlines what sexual health and drug treatment services 
could offer in terms of advice, assessment and intervention. 
 
Sexual health services 
 
Advice on preventing or reducing drug-related harm 
 
• Sexual health services should provide information to all patients on 
harms related to drug use and ways to reduce such harms.  
 
Drug use assessment 
 
• All sexual health services should be competent to sensitively enquire 
about substance use, identify patterns of problematic use and offer advice 
on ways to reduce harm. 
 
Drug misuse intervention 
 
• Once a problem related to drug use has been identified, sexual health 
services should be able to offer:  
 
• basic advice to reduce drug-related harms; 
 
• brief interventions for drug-using behaviours; 
 
• onward referral to drug services where appropriate. 
 
Drug treatment services 
 
Advice on preventing or reducing harm related to sexual activity 
 
• Drug treatment services should provide information to all patients on 
ways to reduce harm from sexual activity.  
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Sexual health assessment 
 
• All substance misuse services should be able to sensitively enquire about 
sexual health, to identify high-risk and harmful behaviours and to offer 
advice on how to reduce harm. 
 
Sexual health interventions 
 
• Once a problem related to sexual activity has been identified, drug 
treatment services should be able to offer:  
 
 basic harm reduction advice regarding high-risk sexual 
behaviours; 
 
 brief intervention regarding high-risk sexual behaviours; 
 
 rapid pregnancy testing; 
 
 rapid HIV and hepatitis testing; 
 
 onward referral to sexual health services where 
appropriate. 
 
6. Are there examples of innovative responses to co-occurring sexual 
activity and drug use problems across Europe? 
 
There have been a number of responses from different European countries to 
problems related to co-occurring sexual activity and drug use. Some of these 
responses focus on defining and monitoring the problem, others on delivering 
services tailored to identify needs (EMDDA, 2016c). 
 
Defining the problem:  
Addictovigilance network, France (1) 
The Addictovigilance network in France has used anonymous questionnaires, 
helplines and case reporting to build a picture of the developing ‘chemsex’ scene 
among MSM across France. This has helped in developing an assessment of need 
and informed the national policy response. 
 
Improving access 
 
Checkpoint (2) — Portugal, Spain, Italy, Greece, Denmark, Netherlands 
Checkpoint is a generic term used to describe a range of community-run HIV and 
STI testing centres, which provide rapid testing to identified at-risk populations, 
for example MSM. These services often lie outside mainstream health systems. In 
some countries, for example Portugal, checkpoints have collaborated to form 
networks with common procedures, training and data collection. The focus has 
                                                        
(1) http://www.addictovigilance.fr 
(2) http://www.lisbongaycircuit.com/checkpoint-lx/ 
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been on rapid testing for HIV infection, syphilis and hepatitis B and C. Many 
checkpoints offer other services, such as more formal harm reduction 
approaches. 
 
Providing information and improving knowledge 
 
QUADROS (quality development in counselling and prevention in the 
context of drugs and sexuality in gay men), Germany (3) 
Established by Deutsche Aidshilfe (DAH) in cooperation with seven partner 
organisations in Berlin, Frankfurt, Nuremberg and Munich, the partnership aims 
to increase knowledge of legal and illegal drugs among MSM, to strengthen 
counselling and referral competencies in gay counselling, prevention projects, 
and AIDS and low-threshold drug counselling sites, and to identify gaps in 
service provision. 
 
Delivering care 
 
Chelsea and Westminster National Health Service (NHS) Foundation Trust 
and Central North West London NHS Foundation Trust, United Kingdom (4) 
Sexual heath and drug treatment providers in one area of London have 
collaborated to provide a team comprising a psychiatrist, a substance misuse 
practitioner and a sexual health practitioner offering appointment-based 
assessment and treatment of problems related to co-occurring drug use and 
sexual activity. If more intensive drug treatment is needed, the team signposts 
clients to the relevant local service.  
 
7. What are the next steps that could be taken to improve the care of people 
with problems related to co-occurring sexual activity and drug use?  
 
There remains uncertainty regarding the prevalence of problems relating to co-
occurring drug use and sexual activity across Europe, both in populations 
accessing treatment and in those who have not sought help. Despite these 
uncertainties, there is increasing evidence of harm, particularly among MSM. 
Many drug treatment and sexual health services acknowledge they do not have 
the knowledge to tackle co-occurring problems, that expertise is not widely 
shared and that treatment pathways are not typically designed to best meet the 
needs of this group.  
 
As yet the evidence base has not clearly identified a better model than the 
current separation of services, although new approaches are beginning to 
emerge. In the absence of a clearer evidence base, it would seem sensible to 
develop services incrementally, rather than suggesting radical and expensive 
redesign. Some relatively simple first steps could improve the overall treatment 
on offer to those with problems relating to co-occurring drug use and sexual 
activity, as follows. 
                                                        
(3) https://www.aidshilfe.de/shop/quadros 
(4) http://clubdrugclinic.cnwl.nhs.uk/ghb-trial/ 
http://www.chelwest.nhs.uk/services/hiv-sexual-health/clinics/john-hunter-clinic-for-sexual-
health 
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Understanding the extent of the problem 
 
• Develop mandatory data collection tools for sexual health and drug 
treatment services to improve the identification of people with problems 
relating to co-occurring drug use and sexual activity. 
 
• Encourage research into problems experienced by those who participate 
in co-occurring drug use and sexual activity to better understand the 
profile of the group, their risk behaviours and treatment needs. 
Furthermore, an economic analysis of the benefits of closer working 
between sexual health and drug treatment services is indicated. 
 
Sharing expertise, developing treatment pathways 
 
• Design and implement training for sexual health staff covering basic 
identification, assessment and brief intervention for drug misuse 
problems. 
 
• Design and implement training for drug treatment staff covering basic 
identification, assessment and brief intervention for problems related to 
sexual activity. 
 
• Encourage closer working between the two services through joint 
educational events at local, national and pan-European level. 
 
• Review treatment pathways adopted for other co-occurring problems, for 
example drug misuse and mental health problems, to learn the lessons of 
what works and what does not. 
 
To conclude, improving data collection and encouraging research is essential if 
the extent of problems related to co-occurring drug use and sexual activity is to 
be better understood. Encouragingly, the expertise needed to identify, advise and 
treat those with such problems is already available within sexual health and drug 
treatment services. The challenge is to share expertise and develop appropriate 
treatment pathways for the benefit of this vulnerable group of people.  
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